JonesTrading analyst Catherine Novack initiated coverage of Dare Bioscience with a Buy rating and $6 price target. The analyst sees Dare as an "undervalued player" in the women’s health space. Contraception is a "blockbuster indication," and the company’s Ovaprene will potentially be the only monthly non-hormonal option on the market, Novack tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DARE:
- Daré Bioscience to Present at the Stifel 2022 Healthcare Conference
- Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022
- Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study
- Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
